BBNX
$10.64
Beta Bionics, Inc., a commercial-stage medical device company, engages in the design, development, and commercialization of solutions to enhance the health and quality of life of insulin-requiring people with diabetes.
Recent News
Beta Bionics Details iLet Automation Strategy, Sales Expansion and Mint Patch Pump Timeline at Conference
Beta Bionics (NASDAQ:BBNX) executives used a conference presentation to outline the company’s strategy in insulin delivery, emphasizing automation, pharmacy reimbursement, and an expanding commercial footprint as key pillars of its growth plan. Positioning iLet around “automation-forward” insulin d
Senseonics launches automated insulin dosing system with 1-year CGM
The company has integrated its Eversense 365 implant with Sequel Med Tech’s insulin delivery system to automate the management of Type 1 diabetes.
Sands Capital Opens $10 Million ServiceTitan Position
ServiceTitan offers cloud software for field service management, generating recurring revenue from a broad base of service professionals.
Beta Bionics, Inc. Q4 2025 Earnings Call Summary
Moby summary of Beta Bionics, Inc.'s Q4 2025 earnings call
Beta Bionics Inc (BBNX) Q4 2025 Earnings Call Highlights: Record Growth Amid Regulatory Challenges
Beta Bionics Inc (BBNX) reports a 54% increase in net sales and significant user base expansion, while addressing FDA compliance issues and anticipating short-term revenue headwinds.